Pidotimod vs Mifamurtide
Head-to-head comparison of Pidotimod (3-L-Pyroglutamyl-L-Thiazolidine-4-Carboxylic Acid) and Mifamurtide (Muramyl Tripeptide Phosphatidylethanolamine) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Pidotimod | Mifamurtide |
|---|---|---|
| Category | Immune Support | Immune Support |
| Full Name | 3-L-Pyroglutamyl-L-Thiazolidine-4-Carboxylic Acid | Muramyl Tripeptide Phosphatidylethanolamine |
| Molecular Weight | 244.27 Da | N/A |
| Half-Life | 3-4 h | 2-4 h |
| Amino Acids | 2 | N/A |
| Typical Dose | 400-800 mg/day | 2 mg/m2 |
| Route | Oral | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 200 | 150 |
| Research Status | Clinical | Clinical |
Pidotimod Benefits
- ✓oral-immune-support
- ✓respiratory-infection-adjunct
- ✓innate-immunity
- ✓adaptive-immunity-support
Mifamurtide Benefits
- ✓macrophage-activation
- ✓innate-immune-signaling
- ✓immune-adjuvant-research
- ✓cytokine-response
Pidotimod Dosing
400 mg PO BID|typically 15-30 days|repeated seasonal cycles in studies
Mifamurtide Dosing
2 mg/m2 IV|2x weekly for 12 weeks|then weekly for 24 weeks in approved regimens
Pidotimod Side Effects
- ⚠nausea
- ⚠diarrhea
- ⚠rash
Mifamurtide Side Effects
- ⚠fever/chills
- ⚠fatigue
- ⚠nausea
Research Overview
Pidotimod
Pidotimod has human data in recurrent infections, especially where immune stimulation or reduced infection frequency is the target. Published work commonly reports improvements in phagocyte function, mucosal defense, and fewer respiratory infection episodes.
Mifamurtide
Mifamurtide has substantial literature as an innate immune activator and is an approved oncology adjunct in some regions. Research centers on NOD-like receptor signaling, macrophage activation, and downstream cytokine effects.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.